The Future of Bone Health: A Field of Dreams
If you have questions, please contact Dudley Phipps at Dudley.Phipps@TheASOP.com.
Osteoporosis (OP) presents an immense and rapidly expanding burden on the healthcare system in Iowa and worldwide. The number of fractures worldwide is expected to double between 2010 and 2040. In the United States population over 50, 50% of women and 25% of men will have one or more fractures in their lifetime. Despite affordable and widely available treatments being available, a healthcare gap exists. Study after study suggests the lack of patient access and patient/provider misconceptions of risk/benefit are major impediments.
With the volume/societal cost of OP fractures and continued footnotes in multiple OP studies indicating a continued/widening care gap, the cost of care continues to accelerate at an increasingly unsustainable rate. In 2016, US Medicare (Fee for Service only) patients suffered 1.29 million osteoporotic fractures (low energy fractures) at an average cost of $21,564 (allowed cost to Medicare and patient cost share) per fracture. This represents $28B in cost. With the US fracture rate expected to exceed two million by 2030, this cost is becoming unsustainable for the healthcare system.
The human cost of fractures, not normally quantified, frequently results in patient pain (often chronic pain), loss of function, decreased independence with increased reliance on family/friends, and corresponding financial burdens to society associated with this demise in function.
There are multiple clinical guidelines for the treatment of osteoporosis, including, but not limited to, the American Association of Clinical Endocrinologists, Bone Health & Osteoporosis Foundation, and the United States Preventative Service Task Force. The field of OP is rapidly evolving, with new treatment sequences, treat-to-target, drug holidays, and treatment goals in a fluid state of change. The excess of guidelines can be confusing, even overwhelming, for overtaxed HCPs. It is often more accessible for the HCP to ignore OP rather than address it.
Given the evolution of guidelines, the loss of healthcare provider (HCP) time available for direct patient care, and the lack of coordinated resources for all HCPs, the United States continues to see a critical gap in the identification/care of OP patients. The Iowa Bone Club is working to increase awareness of guidelines/processes/trends in Iowa (and surrounding states) HCP/Ancillary staff in identifying and treating bone health/osteoporosis.
All times listed are in Central Time. The agenda is subject to change.
Bad to the Bone
Lori B. Siegel, MD, FACP, FACR
Transitioning the Bone Patient from Pediatric to Adult Care
Eric T. Rush, MD, FAAP, CCD
Sequential Therapy in Osteoporosis Treatment
Jared Torkelson, RT(R), PA-C
Bone Health Nutrition
Jonathan C. Hennings, MSN, BSN, BAEd, ARNP, CCD
Pre-Operative Bone Health Risk Assessment
Dudley Phipps, PA-C, CCD
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Bone Club. DMU designates this live activity for 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 5.0 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 5.0 continuing education contact hour(s). Nurses must attend the entire session to receive credit. Partial session credit is prohibited and will be forfeited.
- Other healthcare providers: This live activity is designated for 5.0 AMA PRA Category 1 Credit(s)™.
No ineligible company provided financial support for this continuing education activity.
The speaker(s) will disclose if any pharmaceuticals, medical procedures, and devices discussed are investigational or unapproved by the U.S. Food and Drug Administration (FDA). The determination of educational content and the selection of speakers is the responsibility of the activity director.
Relevant to the content of this educational activity, the following individuals have no conflict(s) with ineligible companies to disclose.
- Jonathan C. Hennings, MSN, BSN, BAEd, ARNP, CCD - Speaker
Relevant to the content of this educational activity, the following individual(s) have conflict(s) with ineligible companies to disclose. All relevant financial relationships have been mitigated.
- Dudley Phipps, PA-C, CCD - Activity Director and Speaker
- Speaker Bureau: Amgen. The financial relationship is not relevant to the content of the educational activity.
- Eric T. Rush, MD, FAAP, CCD - Speaker
- Research support/PI: Alexion, Ultragenyx
- Consultant: Alexion, Ultragenyx, Aruvant, Inozyme, Kyowa Kirin
- Speakers’ bureau: Alexion, Kyowa Kirin
- Scientific advisory board: Global Foundation for Peroxisomal Disorders, Rare Bone Disease Alliance, Osteogenesis Imperfecta Foundation
- Intends to discuss the off-label use of a commercial product or device. They agree to inform the learners before their presentation.
- Lori B. Siegel, MD, FACP, FACR - Speaker
- Speaker/Consultant: Abbvie, Amgen, Boehringer Ingelheim, GSK, Novartis, and UCB. The financial relationships are not relevant to the content of the educational activity.
- Jared Torkelson, RT(R), PA-C - Speaker
- Relationship: Radius
The information provided in this activity is for continuing education. It is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 5.00 AMA PRA Category 1 Credits™
- 5.00 AOA Category 2A
- 5.00 CE Contact Hour(s)
- 5.00 IBON